Market Analysis:
The global orphan drugs market is
predicted to touch USD 2,23,646.51 million at an 11.50% CAGR over the forecast
period (2018-2023), in accordance with the latest Market Research Future (MRFR)
report. Orphan drugs, simply put, are medicinal drugs that are intended to
diagnose, prevent, or treat serious or life-threatening disorders or diseases
which are rare. The reason these drugs are called orphan is owing to the fact
that they are manufactured in minimal quantities with the pharmaceutical sector
having little interest in them.
Orphan drugs are not made by
pharmaceutical industries for economic reasons yet which respond to the need of
public health. Often, orphan drugs are progressive, chronic, and also
disabling. Most of the orphan diseases have curative or effective treatment and
above all have high complexity and low prevalence.
Various factors are propelling the Orphan Drugs Market Companies Report.
These factors, in accordance with the MRFR report, include the rising emphasis
of pharmaceutical companies on orphan drug improvement, rising incidences of
rare diseases, and various initiatives undertaken by the government for orphan
medicine. Additional factors pushing market growth include improving regulatory
framework, growing awareness regarding rare disease, growth in the pharmaceutical
and biotechnology sector, and increase in drug development and research and
development investment.
Access Full Report Details @ https://www.marketresearchfuture.com/reports/orphan-drugs-market-2312
On the contrary, poor healthcare
systems in middle and low-income countries, lack of specificity, and stringent
FDA regulation are factors that may restrict the orphan drugs market growth
over the forecast period.
Key Players:
Bristol
Meyer Squibb, Pfizer Inc., Vertex Pharmaceuticals Inc., Alexion Pharmaceuticals
Inc., Janssen Global Services LLC, Sanofi, Shire Pharmaceutical, Eli Lilly and
Company, Merck KGaA, Takeda Pharmaceutical Company Limited, Biogen, Novartis
AG, Celgene Corporation, Mylan, and F. Hoffmann-La Roche AG
Market Segmentation:
·
The
MRFR report provides a complete segmental analysis of the Orphan
Drugs Market report on the basis of therapy class, drug, sale, and drug
type.
·
Based
on drug type, the orphan drugs market is segmented into non-biologics and
biologics. Of these, the biologics segment will have the largest share in the
market over the forecast period.
·
Based
on sale, the orphan drugs market is segmented into prescribed and
generics.
·
Based
on drug, the orphan drugs market is segmented into adcetris, spinraza,
pomalyst, jakaf, soliris, imbruvica, Keytruda, opdivo, Rituxan, and
Revlimid.
·
Based
on therapy class, the orphan drugs market is segmented into respiratory,
cardiovascular, endocrine, central nervous systems, blood, and oncology.
Regional Analysis:
By region, the orphan drugs market
report covers the latest trends and growth opportunities across the Americas,
Europe, the Asia Pacific (APAC), and the Middle East and Africa (MEA). Of
these, the Americas will dominate the market over the forecast period. This is
chiefly owing to the rising occurrence of rare disorders in the region.
The orphan drugs market in Europe is
predicted to have the second-largest share in the market over the forecast
period. This is owing to the growing number of pharmaceutical companies that
are exporting products within or outside Europe. The majority of the companies
in Europe are engaged in R&D of orphan drugs as per the needs of the
patients. Moreover, strong clinical pipeline, unmet medical necessities,
reimbursement, favorable pricing, and introduction of innovative technologies
are also pushing market growth.
The orphan drugs market in the APAC
region is predicted to grow at the fastest pace over the forecast period. This
is owing to increasing population, growing prevalence of other diseases
including respiratory disorders, cardiovascular & lymphatic systems, and
endocrinology.
No comments:
Post a Comment